PT - JOURNAL ARTICLE AU - William R. Reay AU - Michael P. Geaghan AU - 23andMe Research Team AU - Murray J. Cairns TI - Genome-wide meta-analysis of pneumonia suggests a role for mucin biology and provides novel drug repurposing opportunities AID - 10.1101/2021.01.24.21250424 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.24.21250424 4099 - http://medrxiv.org/content/early/2021/01/26/2021.01.24.21250424.short 4100 - http://medrxiv.org/content/early/2021/01/26/2021.01.24.21250424.full AB - Pneumonia remains one of the leading causes of death worldwide, particularly amongst the elderly and young children. We performed a genome-wide meta-analysis of lifetime pneumonia diagnosis (N=266,277), that encompassed the largest collection of cases published to date. Genome-wide significant associations with pneumonia were uncovered for the first time beyond the major histocompatibility complex region, with three novel loci, including a signal fine-mapped to a cluster of mucin genes. Moreover, we demonstrated evidence of a polygenic effect of common and low frequency pneumonia associated variation impacting several other mucin genes and O-glycosylation, further suggesting a role for these processes in pneumonia pathophysiology. The pneumonia GWAS was then leveraged to identify drug repurposing opportunities, including evidence that supports the use of lipid modifying agents in the prevention and treatment of the disorder. We also propose how polygenic risk could be utilised for precision drug repurposing through pneumonia risk scores constructed using variants mapped to pathways with known drug targets. In summary, we provide novel insights into the genetic architecture of pneumonia susceptibility, with future study warranted to functionally interrogate novel association signals and evaluate the suitability of the compounds prioritised by this study as repositioning candidates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by an NHMRC project grant (1147644). MJC is supported by an NHMRC Senior Research Fellowship (1121474) and a University of Newcastle Faculty of Health and Medicine, Gladys M Brawn Senior Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Newcastle Human Research Ethic Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn accordance with the 23andMe data sharing policies, we are only able to release 10,000 SNPs from our meta-analysis, which we have made available on GitHub (https://github.com/Williamreay/Pneumonia_meta_GWAS_drug_repurposing/tree/master/Summary_statistics). The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Researchers wishing to recapitulate our meta-analysis can apply for access for the 23andMe subset of the study (https://research.23andme.com/dataset-access/), and then meta-analyse with FinnGen release 3 summary statistics as described in our manuscript. Code utilised in this study is available also on GitHub - https://github.com/Williamreay/Pneumonia_meta_GWAS_drug_repurposing.